Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2+ Early Breast Cancer”

Showing 4 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07292207
What this trial is testing

Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer

Who this might be right for
ctDNA MonitoringBreast Cancer
Nagoya City University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07795424
What this trial is testing

Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer

Who this might be right for
Breast CancerHR Positive, HER2 Positive Breast Cancer
Shengjing Hospital 33
Testing effectiveness (Phase 2)Looking for participantsNCT07159451
What this trial is testing

A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 140
Not applicableActive Not RecruitingNCT04854005
What this trial is testing

Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 78

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation